Biopharma in 2018: Vantage Releases Annual Analysis of Pharma, Biotech and Medtech Performance
Macroeconomic trends in Q4 wiped out biopharma’s stock market gains from earlier in 2018, with the S&P Pharmaceuticals Index the only major biopharma index to finish the year in the black. M&A and product licensing volumes were also down, despite notable deals such as Takeda’s $64bn acquisition of Shire and Bristol-Myers Squibb’s $1bn payment to Nektar. Deal-making slowed in the medtech sector too, with fewer acquisitions closed and a corresponding decrease in venture investment rounds.
- Falling share prices in Q4 turned a 15% nine-month climb for the Nasdaq Biotechnology Index into a 9% year-end decline, while the S&P Pharmaceuticals Index only managed a 5% gain.
- M&A activity hit its lowest level since 2009, with 173 total deals; licensing activity also dropped from 2017 levels by both deal count (112) and value measures ($4.94bn).
- The total value of medtech M&A deals came to $27.4bn, a precipitous decline from 2017’s figure of nearly $100bn.
Conversely, 2018 was a banner year for venture financing, with $16.8bn invested in drug development start-ups. Biotech IPOs set new records, with two of the biggest flotations – Moderna and Allogene – occurring in the final months of the year. Medtech IPOs also flourished in the fourth quarter, giving the smaller players a welcome cash injection. The FDA set records as well, with 62 novel drugs approved, and managed a slight reduction in average approval times.
- 37 drug developers raised over $100m in financing, more than double the number in 2017.
- Biotech IPOs raised a record $7.23bn, with the average amount raised tipping over $100m for the first time.
- A total of $695m was raised by device companies going public in the fourth quarter, more than any other three-month period since Vantage started tracking medtech listings in 2013.
- The FDA’s 2018 class of novel drugs is forecast to sell $24bn by 2023, including new migraine drugs Aimovig, Emgality and Ajovy; Alnylam's RNAi therapeutic Onpattro; and 17 new cancer drugs.
“The progress of biopharma and medtech companies last year paints a mixed picture,” said Amy Brown, co-author of the Vantage Pharma, Biotech and Medtech 2018 in Review report. “However, there are signs of health, if the industry is able to capitalize on them."
To download a complimentary copy of the report, visit http://www.evaluate.com/2018Review.
Vantage, formerly known as EP Vantage, provides award-winning, thought-provoking news and insights into current and future developments in the industry, and is the only pharmaceutical news service underpinned by Evaluate’s commercial intelligence. Visit www.evaluate.com/vantage for free access to daily, data-driven news for pharma, biotech, and medtech.
On Twitter: @Vantageanalysis.
About Evaluate Ltd
Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries. For more information on how we give industry-leading companies the time and understanding to drive better decisions, visit us at www.evaluate.com.
On Twitter: @EvaluatePharma, @EvaluateMedtech
Evaluate and Vantage
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Quinbrook Infrastructure Partners Launches with Mercatus26.3.2019 16:00:00 EET | Tiedote
Mercatus, a leading alternative asset and investment management platform, today announced the initial launch of Quinbrook Infrastructure Partners with the Mercatus Investment Lifecycle Management (ILM) Platform. Quinbrook invests in a wide range of low carbon and renewable energy infrastructure assets spanning onshore wind, utility scale and distributed solar PV, battery storage, peaking capacity and ‘smart grids’. Quinbrook recently announced final close on its latest strategy securing over USD 1.6 billion from institutional investors to support ‘value add’ investments in the US, UK and Australian markets. The Mercatus Investment Lifecycle Management (ILM) Platform systematizes and centralizes asset, fund, and portfolio data to give investors accurate analytics and real-time performance, risk, and ESG insights. “Mercatus offered us the fastest time-to-value on our biggest need: streamlining how we work with our rapidly expanding stable of portfolio companies and preparing for the digi
AerSale to Build Next Aero Air / Erickson Aero Tanker for Wildfire Suppression26.3.2019 16:00:00 EET | Tiedote
AerSale ®, a global supplier of mid-life aircraft, engines, used serviceable material, and maintenance, repair, and overhaul (MRO) services, announced today it has signed a contract with Aero Air / Erickson Aero Tanker to build another firefighting air tanker for the company’s fleet at AerSale’s MRO facility in Goodyear, Arizona. Conversion of the 6th MD-87 aircraft, formally begins on April 1 and will mark the sixth such aircraft modification AerSale has completed at Goodyear. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005165/en/ AerSale to Build Next Aero Air / Erickson Aero Tanker for Wildfire Suppression (Photo: Business Wire) “The Erickson Aero Tanker is a very versatile fire bomber and we are proud to continue our work to expand their fleet and add more aerial firefighting power to the skies,” said Charlie McDonald, Senior Vice President MRO Services at AerSale. “This modified aircraft will rank among the bes
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection26.3.2019 15:30:00 EET | Tiedote
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg; FTC/TAF) dual nucleoside reverse transcriptase inhibitor (NRTI) backbone, and is the smallest INSTI-based triple-therapy STR available. Biktarvy is the first HIV product that Gilead will launch and commercialize in Japan directly through its local subsidiary, Gilead Sciences K.K. In the United States, Biktarvy has a Boxed Warning in its product label regarding the risk of post-treatment acute exacerbation of hepatitis B. See below for U.S. Important Safety Information as well as the Biktar
Clearpath Brings Velodyne Lidar Technology to Robotics Community as Value-Added Partner26.3.2019 15:00:00 EET | Tiedote
Velodyne Lidar, Inc. today announced Clearpath Robotics has become a value-add partner to offer its groundbreaking lidar sensors for the Clearpath research robot platform. Clearpath Robotics, headquartered in Canada, offers Velodyne sensors to academic and corporate research organizations on its mobile robots for survey and inspection, oil and gas, agriculture, materials handling and other applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005148/en/ Clearpath’s robotic solutions utilize Velodyne’s state-of-the-art lidar technology, which boasts industry-leading resolution, range, and field of view. (Photo: Business Wire) Clearpath’s robotic solutions utilize Velodyne’s state-of-the-art lidar technology, which boasts industry-leading resolution, range, and field of view. Velodyne sensors create a 360° real-time map of the environment, allowing the robot to detect and avoid obstacles for safe autonomous naviga
Fifth Annual Fortune 500 Employment Brand Report Published by WilsonHCG26.3.2019 15:00:00 EET | Tiedote
WilsonHCG, a multi-award-winning global talent solutions provider, released its fifth annual Fortune 500 Employment Brand Report. The report analyzes and ranks the employment brand of each of the Fortune 500 companies based on more than 17,000 data points around six key employment branding and promotion categories. It also identifies trends and changes to employee attraction and engagement throughout the hiring process. “Globally, this is the most competitive hiring environment in history,” said John Wilson, CEO of WilsonHCG. “One key finding from the report, many of the high ranked companies are providing candidates with a hyper-personalized experience. A positive and personalized candidate experience is more important than ever before.” Each company within the Fortune 500 was evaluated on the scope of six key employment brand categories grouped into four areas of the hiring process: Awareness & Attraction, Recruitment, Candidate Experience, and Employee Experience. “Executive leaders
ABB Wins Contract to Power the First Chinese-Built Cruise Vessel26.3.2019 14:29:00 EET | Tiedote
ABB has been awarded a contract to supply an integrated package, including two Azipod® steerable propulsion systems, for the construction of China’s first ever home-grown cruise ship. ABB’s deep domain knowledge in cruise technology coupled with its local expertise makes it the perfect partner to support this significant milestone in the evolution of China’s shipbuilding industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005501/en/ The Azipod® steerable propulsion systems, also used for the construction of China’s first ever home-grown cruise ship, due for delivery in 2023. (Photo: Business Wire) The 323-meter vessel, due for delivery in 2023, can accommodate 5,000 passengers and is designed to suit the tastes of Chinese cruise travelers whose numbers are expected to rise to 8-10 million annually by 2025, according to industry body Cruise Lines International Association (CLIA). “With this project, China is making
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme